Latest Earnings Results: Q2 '26
Estimated EPS
$0.02
Reported EPS
$0.36
Surprise
+1383.25%
Estimated Rev
$221.15M
Reported Rev
$256.15M
Surprise
+15.83%
• Reported GAAP EPS of $0.40 up 21.21% YoY • Reported revenue of $256.15M up 31.74% YoY
Bullish Takeaway
Corcept Therapeutics is driving growth through the successful commercial launch of Lifyorli, positive clinical trial results for Korlym in hypercortisolism, and maintains a solid liquidity position to support future operations.
Bearish Takeaway
Corcept Therapeutics faces significant risks from ongoing legal litigation, potential revenue erosion from generic competition for Korlym, and the negative impact of government price-reducing regulations on future company profitability.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.56 | -- | -- | N/A |
Q2 '26 | $0.02 | $0.36 | 1383.25% | BEAT |
Q1 '26 | -$0.11 | -$0.30 | -176.52% | MISSED |
Q4 '25 | $0.33 | $0.20 | -39.30% | MISSED |
Q3 '25 | $0.13 | $0.16 | 18.98% | BEAT |
